MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 565228 | Name: ONO-8711
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

ONO-8711 is a selective EP1 antagonist. ONO-8711 targets Cox-2/PGE2 axis to inhibit tumor progression. Findings suggest that a combination of ONO-8711 and EGCG is a potential treatment for hepatocellular carcinoma (HCC) therapy.

Chemical Structure

ONO-8711
ONO-8711
CAS#216158-34-8

Theoretical Analysis

MedKoo Cat#: 565228

Name: ONO-8711

CAS#: 216158-34-8

Chemical Formula: C22H30ClNO4S

Exact Mass: 439.1584

Molecular Weight: 440.00

Elemental Analysis: C, 60.06; H, 6.87; Cl, 8.06; N, 3.18; O, 14.54; S, 7.29

Price and Availability

Size Price Availability Quantity
5mg USD 675.00
10mg USD 965.00
25mg USD 1,495.00
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
ONO-8711; ONO 8711; ONO8711
IUPAC/Chemical Name
6-[(2R,3S)-3-[[[(4-Chloro-2-methylphenyl)sulfonyl]amino]methyl]bicyclo[2.2.2]oct-2-yl]-5Z-hexenoic acid
InChi Key
VVEXPDRCGCQELD-CFDZEDGGSA-N
InChi Code
InChI=1S/C22H30ClNO4S/c1-15-13-18(23)11-12-21(15)29(27,28)24-14-20-17-9-7-16(8-10-17)19(20)5-3-2-4-6-22(25)26/h3,5,11-13,16-17,19-20,24H,2,4,6-10,14H2,1H3,(H,25,26)/b5-3-/t16?,17?,19-,20-/m0/s1
SMILES Code
O=C(O)CCC/C=C\[C@H]1C(CC2)CCC2[C@@H]1CNS(=O)(C3=CC=C(Cl)C=C3C)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 440.00 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Yang H, Wang M, Sun H, Zhu S, Jin J. Synergetic Effect of EP1 Receptor Antagonist and (-)-Epigallocatechin-3-gallate in Hepatocellular Carcinoma. Pharmacology. 2019;104(5-6):267-275. doi: 10.1159/000502076. Epub 2019 Aug 21. PMID: 31434088. 2. Taub M, Parker R, Mathivanan P, Ariff MA, Rudra T. Antagonism of the prostaglandin E2 EP1 receptor in MDCK cells increases growth through activation of Akt and the epidermal growth factor receptor. Am J Physiol Renal Physiol. 2014 Sep 1;307(5):F539-50. doi: 10.1152/ajprenal.00510.2013. Epub 2014 Jul 9. PMID: 25007872; PMCID: PMC4154115. 3. Wada N, Matsumoto S, Kita M, Watanabe M, Hashizume K, Kakizaki H. Effect of intrathecal administration of E-series prostaglandin 1 receptor antagonist in a cyclophosphamide-induced cystitis rat model. Int J Urol. 2013 Feb;20(2):235-40. doi: 10.1111/j.1442-2042.2012.03126.x. Epub 2012 Aug 26. PMID: 22925406. 4. Takeuchi K, Aihara E, Sasaki Y, Nomura Y, Ise F. Involvement of cyclooxygenase-1, prostaglandin E2 and EP1 receptors in acid-induced HCO3- secretion in stomach. J Physiol Pharmacol. 2006 Dec;57(4):661-76. PMID: 17229989.
In vitro protocol:
1. Yang H, Wang M, Sun H, Zhu S, Jin J. Synergetic Effect of EP1 Receptor Antagonist and (-)-Epigallocatechin-3-gallate in Hepatocellular Carcinoma. Pharmacology. 2019;104(5-6):267-275. doi: 10.1159/000502076. Epub 2019 Aug 21. PMID: 31434088. 2. Taub M, Parker R, Mathivanan P, Ariff MA, Rudra T. Antagonism of the prostaglandin E2 EP1 receptor in MDCK cells increases growth through activation of Akt and the epidermal growth factor receptor. Am J Physiol Renal Physiol. 2014 Sep 1;307(5):F539-50. doi: 10.1152/ajprenal.00510.2013. Epub 2014 Jul 9. PMID: 25007872; PMCID: PMC4154115.
In vivo protocol:
1. Wada N, Matsumoto S, Kita M, Watanabe M, Hashizume K, Kakizaki H. Effect of intrathecal administration of E-series prostaglandin 1 receptor antagonist in a cyclophosphamide-induced cystitis rat model. Int J Urol. 2013 Feb;20(2):235-40. doi: 10.1111/j.1442-2042.2012.03126.x. Epub 2012 Aug 26. PMID: 22925406. 2. Takeuchi K, Aihara E, Sasaki Y, Nomura Y, Ise F. Involvement of cyclooxygenase-1, prostaglandin E2 and EP1 receptors in acid-induced HCO3- secretion in stomach. J Physiol Pharmacol. 2006 Dec;57(4):661-76. PMID: 17229989.
1: Chen C, Guan J, Gu X, Chu Q, Zhu H. Prostaglandin E2 and Receptors: Insight Into Tumorigenesis, Tumor Progression, and Treatment of Hepatocellular Carcinoma. Front Cell Dev Biol. 2022 Mar 10;10:834859. doi: 10.3389/fcell.2022.834859. PMID: 35356289; PMCID: PMC8959932. 2: Golden J, Illingworth L, Kavarian P, Escobar O, Delaplain P, Isani M, Wang J, Lim J, Bowling J, Bell B, Gayer CP, Grishin A, Ford HR. EP2 Receptor Blockade Attenuates COX-2 Upregulation During Intestinal Inflammation. Shock. 2020 Sep;54(3):394-401. doi: 10.1097/SHK.0000000000001444. PMID: 31490357; PMCID: PMC7051888. 3: Yang H, Wang M, Sun H, Zhu S, Jin J. Synergetic Effect of EP1 Receptor Antagonist and (-)-Epigallocatechin-3-gallate in Hepatocellular Carcinoma. Pharmacology. 2019;104(5-6):267-275. doi: 10.1159/000502076. Epub 2019 Aug 21. PMID: 31434088. 4: Nodai T, Hitomi S, Ono K, Masaki C, Harano N, Morii A, Sago-Ito M, Ujihara I, Hibino T, Terawaki K, Omiya Y, Hosokawa R, Inenaga K. Endothelin-1 Elicits TRP- Mediated Pain in an Acid-Induced Oral Ulcer Model. J Dent Res. 2018 Jul;97(8):901-908. doi: 10.1177/0022034518762381. Epub 2018 Mar 8. PMID: 29518348. 5: Shiow LR, Favrais G, Schirmer L, Schang AL, Cipriani S, Andres C, Wright JN, Nobuta H, Fleiss B, Gressens P, Rowitch DH. Reactive astrocyte COX2-PGE2 production inhibits oligodendrocyte maturation in neonatal white matter injury. Glia. 2017 Dec;65(12):2024-2037. doi: 10.1002/glia.23212. Epub 2017 Aug 30. PMID: 28856805; PMCID: PMC5753598. 6: Ito M, Ono K, Hitomi S, Nodai T, Sago T, Yamaguchi K, Harano N, Gunnjigake K, Hosokawa R, Kawamoto T, Inenaga K. Prostanoid-dependent spontaneous pain and PAR2-dependent mechanical allodynia following oral mucosal trauma: involvement of TRPV1, TRPA1 and TRPV4. Mol Pain. 2017 Jan;13:1744806917704138. doi: 10.1177/1744806917704138. PMID: 28381109; PMCID: PMC5407658. 7: Nasrallah R, Hassouneh R, Zimpelmann J, Karam AJ, Thibodeau JF, Burger D, Burns KD, Kennedy CR, Hébert RL. Prostaglandin E2 increases proximal tubule fluid reabsorption, and modulates cultured proximal tubule cell responses via EP1 and EP4 receptors. Lab Invest. 2015 Sep;95(9):1044-55. doi: 10.1038/labinvest.2015.79. Epub 2015 Jun 29. PMID: 26121313. 8: Takeuchi K, Ise F, Takahashi K, Aihara E, Hayashi S. H2S-induced HCO3- secretion in the rat stomach--involvement of nitric oxide, prostaglandins, and capsaicin-sensitive sensory neurons. Nitric Oxide. 2015 Apr 30;46:157-64. doi: 10.1016/j.niox.2014.11.001. Epub 2014 Nov 7. PMID: 25460323. 9: Taub M, Parker R, Mathivanan P, Ariff MA, Rudra T. Antagonism of the prostaglandin E2 EP1 receptor in MDCK cells increases growth through activation of Akt and the epidermal growth factor receptor. Am J Physiol Renal Physiol. 2014 Sep 1;307(5):F539-50. doi: 10.1152/ajprenal.00510.2013. Epub 2014 Jul 9. PMID: 25007872; PMCID: PMC4154115. 10: Thibodeau JF, Nasrallah R, Carter A, He Y, Touyz R, Hébert RL, Kennedy CRJ. PTGER1 deletion attenuates renal injury in diabetic mouse models. Am J Pathol. 2013 Dec;183(6):1789-1802. doi: 10.1016/j.ajpath.2013.08.022. Epub 2013 Oct 8. PMID: 24113456. 11: Sekine S, Kimura T, Motoyama M, Shitara Y, Wakazono H, Oida H, Horie T. The role of cyclophilin D in interspecies differences in susceptibility to hepatotoxic drug-induced mitochondrial injury. Biochem Pharmacol. 2013 Nov 15;86(10):1507-14. doi: 10.1016/j.bcp.2013.08.027. Epub 2013 Sep 3. PMID: 24012842. 12: Kitta T. Editorial Comment from Dr Kitta to effect of intrathecal administration of E-series prostaglandin 1 receptor antagonist in a cyclophosphamide-induced cystitis rat model. Int J Urol. 2013 Feb;20(2):241. doi: 10.1111/j.1442-2042.2012.03156.x. Epub 2012 Sep 13. PMID: 22973832. 13: Ishizuka O. Editorial Comment from Dr Ishizuka to effect of intrathecal administration of E-series prostaglandin 1 receptor antagonist in a cyclophosphamide-induced cystitis rat model. Int J Urol. 2013 Feb;20(2):240. doi: 10.1111/j.1442-2042.2012.03145.x. Epub 2012 Sep 7. PMID: 22958174. 14: Wada N, Matsumoto S, Kita M, Watanabe M, Hashizume K, Kakizaki H. Effect of intrathecal administration of E-series prostaglandin 1 receptor antagonist in a cyclophosphamide-induced cystitis rat model. Int J Urol. 2013 Feb;20(2):235-40. doi: 10.1111/j.1442-2042.2012.03126.x. Epub 2012 Aug 26. PMID: 22925406. 15: Jin J, Chang Y, Wei W, He YF, Hu SS, Wang D, Wu YJ. Prostanoid EP1 receptor as the target of (-)-epigallocatechin-3-gallate in suppressing hepatocellular carcinoma cells in vitro. Acta Pharmacol Sin. 2012 May;33(5):701-9. doi: 10.1038/aps.2012.13. PMID: 22555372; PMCID: PMC4010354. 16: Tanaka I, Nagase K, Tanase K, Aoki Y, Akino H, Yokoyama O. Modulation of stretch evoked adenosine triphosphate release from bladder epithelium by prostaglandin E₂. J Urol. 2011 Jan;185(1):341-6. doi: 10.1016/j.juro.2010.09.042. PMID: 21075387. 17: Mizuguchi S, Ohno T, Hattori Y, Ae T, Minamino T, Satoh T, Arai K, Saeki T, Hayashi I, Sugimoto Y, Narumiya S, Saigenji K, Majima M. Roles of prostaglandin E2-EP1 receptor signaling in regulation of gastric motor activity and emptying. Am J Physiol Gastrointest Liver Physiol. 2010 Nov;299(5):G1078-86. doi: 10.1152/ajpgi.00524.2009. Epub 2010 Aug 26. PMID: 20798358. 18: Rodríguez-Lagunas MJ, Martín-Venegas R, Moreno JJ, Ferrer R. PGE2 promotes Ca2+-mediated epithelial barrier disruption through EP1 and EP4 receptors in Caco-2 cell monolayers. Am J Physiol Cell Physiol. 2010 Aug;299(2):C324-34. doi: 10.1152/ajpcell.00397.2009. Epub 2010 May 19. PMID: 20484658. 19: Kaneshiro T, Okumura M, Maalouf S, Uflacker A, Maruyama T, Kawamori T. Inhibition of prostaglandin E(2) signaling through the EP(1) receptor does not affect prostacyclin production in human endothelial cells. Prostaglandins Other Lipid Mediat. 2009 Nov;90(1-2):31-6. doi: 10.1016/j.prostaglandins.2009.07.003. Epub 2009 Jul 30. PMID: 19647091; PMCID: PMC2767438. 20: Carlson NG, Rojas MA, Black JD, Redd JW, Hille J, Hill KE, Rose JW. Microglial inhibition of neuroprotection by antagonists of the EP1 prostaglandin E2 receptor. J Neuroinflammation. 2009 Feb 17;6:5. doi: 10.1186/1742-2094-6-5. PMID: 19222857; PMCID: PMC2649915.